PANDEMIC PROVIDER WEEKLY BROWN BAG

Updated March 30, 2021


Brown Bag for COVID-19 Vaccine Providers

- Provide resources
- Useful links




ADHS COVID-19 Vaccine Website

azhealth.gov/covid19vaccine



ADHS Find Vaccine webpage <u>azhealth.gov/findvaccine</u>

- Each jurisdiction's current vaccination phase
- The locations of vaccination sites



<u>Arizona Expands COVID-19 Vaccination Eligibility to All</u>

- All Arizonans 16 and older at state-operated COVID-19 vaccination sites
- Wednesday March 24th
- Use the patient portal at <u>podvaccine.azdhs.gov</u> to make an appointment for a relative
- ADHS opens appointments at 11am every Friday



Douglas A. Ducey | Governor Cara M. Christ, MD, MS | Director

News Release

For Immediate Release: March 22, 2021 Media Contact: Steve Elliott Email: pio@azdhs.gov

Arizona Expands COVID-19 Vaccination Eligibility to All Arizonans age 16 and up can be vaccinated at state sites

PHOENIX — Registration at Arizona's state-operated COVID-19 vaccination sites in Maricopa, Pima and Yuma counties will be open to all Arizonans 16 and older beginning at 8 a.m. Wednesday, March 24, Governor Doug Ducey and the Arizona Department of Health Services announced today.

"Our goal has been and remains to get vaccine into the community as quickly, widely and equitably as possible," said Governor Ducey. "Given a thorough review of vaccination data, anticipated vaccine supply, and current demand among prioritized groups, now is the time to take this critical next step."

As of this morning, Arizona has administered 2,904,159 doses of COVID-19 vaccine to 1,831,456 individuals, including 1,136,413 who are fully vaccinated. As of Monday morning, there were over 58,000 appointments still available from Friday's release.

The change announced today advances a hybrid approach that had been based on age and also has had counties vaccinating frontline essential workers. It applies to appointments still available for this week at state sites in Maricopa and Pima counties.


"We anticipate more and more vaccine reaching Arizona heading into April, making it possible now to expand prioritization," said Dr. Cara Christ, director of the Arizona Department of Health Services. "We have been flexible and nimble throughout, while expanding the availability of state sites to vaccinate large numbers of people rapidly."

ADHS now opens appointments at 11 a.m. each Friday for State Farm Stadium in Glendale, Arizona State
University's Phoenix Municipal Stadium in Tempe, Chandler-Gilbert Community College, the University of

Pandemic Provider Onboarding

START NOW

It takes time to add providers to the systems



Pandemic Vaccine Provider Onboarding Tool

- Wait until you're at the facility to onboard so you can upload photos of inside of units
- Read through forms for important requirements

CDC Agreement

Per the CDC Agreement, COVID-19 vaccines must be recorded in the vaccine recipient's record, the required information reported to the relevant state, local, or territorial public health authority, and decremented from the inventory within 24 hours of administration.

Pandemic Vaccine Provider Onboarding Tool

How to get started

- 1. Click the onboarding link Pandemic Vaccine Provider Onboard Form 1 and fill out the form
- 2. Click submit this will take you to survey queue page
- 3. Continue to complete other surveys that are not marked "Complete." A link to this page will be emailed to you

Contact and Shipping Information

1



- Facility location information
- · Signatory provider info (title, license, NPI)
- · Primary and backup vaccine coordinator information
- Not sure if you're a VFC/VCA provider? Select no when it asks if you are a VFC provider; this is not necessary to participate





Storage and Handling

- · Photos of your cold storage units showing the inside of the units
- · Brand and model of each cold storage unit
- · Data logger usage info
- · Read requirements





Arizona State Immunization Information System (ASIIS)

- · Are you currently entering/transferring immunization data into ASIIS?
- · Read requirements






Vaccine Planning


· Read through content so you can plan and be prepared





- CMO & CEO signatures
- For organizations: follow the instructions for Section A in FAQs. Follow the decision tree on the final page to determine whether you need to follow organization instructions






- Facility type
- · Populations served
- Storage unit capacity
- · Must be signed by the signatory provider/the primary vaccine coordinator







- · Submit multiple times one for each prescribing provider
- · Enter each prescriber's name, title, and license number

Governor Executive Orders

November 18, 2020 - Executive Order: 2020-57

- Enhanced Surveillance Advisory Monitoring the Administration of COVID-19 Vaccination
- Data elements that must be reported

December 30, 2020 - Executive Order to Accelerate COVID-19 Vaccine Distribution

- News Release
- Allows for reallocation of doses

<u>January 26, 2021 - Executive Order To Accelerate COVID-19 Vaccine Distribution</u>

- News Release
- Providers administering COVID-19 vaccines must complete daily survey due every 24 hours reporting:
 - COVID-19 vaccine administration appointment capacity and availability per day
 - Number of COVID-19 vaccine administration appointments currently scheduled each day
 - Date furthest in the future that a scheduled appointment is calendared for COVID-19 vaccine administration

Required Reporting

- ASIIS
 - o for inventory accounting and dose administration data within 24 hours
 - Required even if you use an EHR, ADHS VMS app, etc.
 - Verify ASIIS Lot Number> Reconciliation page (ASIIS Inventory) matches doses on hand
- Executive Order daily survey
 - For appt capacity/scheduled/available
 - Emailed to providers with doses in ASIIS
- ArcGIS Survey 123
 - To identify every vaccination events schedule (open or closed) for GIS mapping
 - Emailed to providers as they are allocated doses
- CDC VaccineFinder daily inventory
- Survey as needed for providers who are not using doses allocated to them in a timely manner
- County surveys as required by your local jurisdiction

Your ASIIS inventory is used by local, state, and federal leaders to make vaccine allocation decisions - It MUST be accurate

<u>VaccineFinder</u>

The "organization email" listed in Section A of the CDC Agreement will get an email from vaccinefinder@auth.castlighthealth.com to sign up

- Daily reporting of on-hand inventory quantities to CDC through VaccineFinder will remain a requirement
- Activating a location to display to the public will be optional
- All sites default to 'NOT display to the public' until the provider changes the display settings through the COVID-19 Locating Health Portal
- Providers can update the display to the public function at any time
- Once the COVID-19 vaccine locations are launched in VaccineFinder.org, changes will show publicly within 24 hours

Note: Check/update phone number in provider portal before making site public

COVID-19 Vaccine Locations Displayed in Spanish

AIPO Train

- Training on ordering, receiving, and accounting for doses in ASIIS
- Information on data loggers setting up, downloading data
- Onboarding resources
- Mass immunization
- Recording of brown bag webinar is updated weekly

Questions about AIPO Train? Email AIPOTrain@azdhs.gov

How to Register or Login to AIPO TRAIN

Register

- 1. Go to https://aipo.myabsorb.com/?KeyName=PandemicProviders
- 2. Enter required fields
- 3. Select Sign up
- 4. Click email activation link (important)

Log In

- Go to https://aipo.myabsorb.com/#/login
- Enter username and password (username will be email address)
- Select Log In

For existing AIPO Train users: Enter enrollment key "PandemicProviders" to access pandemic-specific training

Administration Fee

CMS has a toolkit to help health care providers prepare to administer vaccines. Because the initial supply of COVID-19 vaccines will be federally purchased, this toolkit primarily focuses on coverage of vaccine administration. Vaccine doses purchased with U.S. taxpayer dollars will be given to the American people at no cost. Providers that participate in the CDC COVID-19 Vaccination Program contractually agree to administer a COVID-19 vaccine regardless of an individual's ability to pay and regardless of their coverage status, and also may not seek any reimbursement, including through balance billing, from a vaccine recipient. Providers who have questions about billing or reimbursement of vaccine administration for patients covered by private insurance or Medicaid should contact the respective health plan or state Medicaid agency. People without health insurance or whose insurance does not provide coverage of the vaccine can also get COVID-19 vaccine at no cost. Providers administering the vaccine to people without health insurance or whose insurance does not provide coverage of the vaccine can request reimbursement for the administration of the COVID-19 vaccine through the Provider Relief Fund

Facilities cannot bill patients for the cost or admin fee for COVID-19 vaccines.

AHCCCS

COVID vaccinators will need to be enrolled with AHCCCS in order to be able to bill the vaccine administration fee for AHCCCS beneficiaries.

Providers can <u>register with AHCCCS here</u>.

CVX Code and CPT Code Resources

- Helpful for Billing
- Helpful for Uploading Data in EHR and ASIIS
- Arizona HL7 Specific Rules

TAPI - The Arizona Partnership for Immunizations (State immunization coalition)

- COVID-19 Resources
- COVID-19 Vaccine Billing Policy Information
- Resources for immunizations at off-site locations

CDC Guidance for Planning Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations

CDC has issued revised <u>Guidance for Planning Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations</u> to assist with jurisdictional planning and implementation of satellite, temporary, or off-site vaccination clinics by public and private vaccination organizations.

The guidance is broken down into four categories:

- Planning activities
- Pre-clinic activities
- During the clinic activities
- Post-clinic activities

The guidance also provides information on additional considerations required during the COVID-19 pandemic, including physical distancing, personal protective equipment (PPE), and enhanced sanitation efforts


CDC COVID-19 Vaccine Training Modules

- Pfizer training
- Moderna training
- Janssen added
- General Overview of Immunization Best Practices




Public Health Foundation Training Plan

- Compiled list of trainings provided by CDC
- Basic and COVID-19-vaccine-specific information



CDC COVID-19 Vaccination Clinical Resources




<u>Interim Considerations: Preparing for the Potential</u> <u>Management of Anaphylaxis at COVID-19 Vaccination Sites</u>

- Emergency equipment that should be immediately available
- Routine observation periods following COVID-19 vaccination
- Early recognition of anaphylaxis
- Management of anaphylaxis at a COVID-19 vaccination location
- Considerations for anaphylaxis management in special populations
- Patient counseling
- Reporting anaphylaxis

Locations administering COVID-19 vaccines should adhere to CDC guidance, including screening recipients for contraindications and precautions, having necessary supplies and staff members available to manage anaphylaxis, implementing recommended post vaccination observation periods, and immediately treating suspected anaphylaxis with intramuscular epinephrine injection.

<u>Interim Clinical Considerations for Use of COVID-19 Vaccines Currently</u> <u>Authorized in the United States</u>

- Appendix A: Vaccine administration errors and deviations
- Appendix B: Triage of Persons presenting for mRNA COVID-19 Vaccination
- Appendix D: Potential Characteristics of allergic reactions, vasovagal reactions, and vaccine side effects following mRNA COVID-19 vaccination
- Summary Document for Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States
- COVID-19 Vaccine Administration Errors and Deviations




CDC Vaccine Storage and Handling Toolkit

Updated with a COVID-19 Vaccine Addendum March 4, 2021 (Page 50):

- Clarify COVID-19 vaccination provider requirements
- Include language related to FDA authorization of COVID-19 vaccine products
- Storage and handling information on all three vaccines

Jurisdictions and providers are encouraged to sign up for email alerts on the <u>Vaccine Storage and Handling Toolkit</u> website to be notified when updates are made or check the website often.



VAERS Reporting and Safety Info - <u>vaers.hhs.gov</u>

VAERS accepts all reports from everyone regardless of the plausibility of the vaccine causing the event or the clinical seriousness of the event.



CDC v-safe system

- Give patients a v-safe information sheet at the time of vaccination
- Suggested healthcare provider script: CDC has created a way for you to report how you feel after COVID-19 vaccination through a smartphone-based tool that uses text messaging and web surveys to check in with you. Here (or in your packet) is a v-safe information sheet with more details and simple instructions to sign up.
- If you have an existing capability to push automated notifications to patients post-vaccination, consider adding the following notification to remind patients to participate in v-safe 24 hours after vaccination: CDC: A healthy reminder to use v-safe, the after-vaccination health checker! Sign up or log on to share your experience: add v-safe link here.
- Poster and website translated into multiple languages





What is v-safe?

V-safe is a smartphone-based tool that uses text messaging and web surveys to provide personalized health check-ins after you receive a COVID-19 vaccination. Through v-safe, you can quickly tell CDC if you have any side effects after getting the COVID-19 vaccine. Depending on your answers, someone from CDC may call to check on you. And v-safe will remind you to get your second COVID-19 vaccine dose if you need one.

Your participation in CDC's *v-safe* makes a difference – it helps keep COVID-19 vaccines safe.

How can I participate?

Once you get a COVID-19 vaccine, you can enroll in **v-safe** using your smartphone. Participation is voluntary and you can opt out at any time. You will receive text messages from **v-safe** around 2pm local time. To opt out, simply text "STOP" when **v-safe** sends you a text message. You can also start **v-safe** again by texting "START."

How long do v-safe check-ins last?

During the first week after you get your vaccine, *v-safe* will send you a text message each day to ask how you are doing. Then you will get check-in messages once a week for up to 5 weeks. The questions *v-safe* asks should take less than 5 minutes to answer. If you need a second dose of vaccine, *v-safe* will provide a new 6-week check-in process so you can share your second-dose vaccine experience as well. You'll also receive check-ins 3, 6, and 12 months after your final dose of vaccine.

Is my health information safe?

Yes. Your personal information in *v-safe* is protected so that it stays confidential and private.*

To the extent V-safe use existing information systems managed by CDC, FDA, and other federal agencies, the systems employ sirt is security measures appropriate for the data is level of annitivity. These measures comply, where applicable, with the following federal laws, including the Privacy Lot of 1974; standards senacted that are consistent with the Health insurance Portability and Accountability Act of 1996 (HIPAA); the Federal Information Security Management Act, and the Freedom of Information Act.



Use your smartphone to tell CDC about any side effects after getting the COVID-19 vaccine. You'll also get reminders if you need a second vaccine dose.



smar phono phonoser at vsafe.cdc.gov

OR
Aim your smartphone's de

Immunization Action Coalition - immunize.org

- Info on administering vaccines
- Handouts for staff and patients
- "Ask the Experts" page
 - Includes <u>COVID-19 vaccines</u>
- Option to sign up for IAC Express email
 - Weekly email with updates to information and resources



Instead of a VIS, we will use the EUA fact sheet

Routine vaccines are given with a Vaccine Information Statement (VIS) COVID-19 vaccines under the Emergency Use Authorization (EUA) will be given with an EUA Factsheet.

- Pfizer Fact Sheet
- Pfizer EUA fact sheet translated in other languages
- Moderna Fact sheet
- Moderna EUA fact sheet translated in other languages
- Janssen Fact Sheet
- Janssen EUA fact sheet translated in other languages


Consent form

- There is no Federal requirement for informed consent relating to immunization.
- ADHS has created a <u>consent form template</u> for providers to use if they do not have one of their own.
- We strongly suggest the consent form be used along with the corresponding CDC Pre-Vaccination Form for the appropriate vaccine being administered.
- Spanish consent form is also available

ADHS COVID-19 Vaccine Consent Form OF HEALTH SERVICES Use this form in conjunction with the CDC Pre-Vaccination Checklist for COVID-19 Vaccines. **Patient Information** Middle Name (optional) Last Name First Name Mother's Maiden Name (Optional) Date of Birth (MM/DD/YYYY) Gender Address Apartment Number City State No address available Phone Number SSN or Driver's License/State ID Number **Insurance Information** Do you have insurance? Yes No Medicare ID Number or SSN Plan Name Plan Group ID # Plan Individual ID# Name of Person Covered By Plan Covered Person's Date of Birth Plan Responsible Person Name Private Insurance Address and Phone Number (If Available) any insurance or other third-party benefits available for the administration fee of the COVID-19 vaccine provided to me. I agree to forward to insurance and other third-party payments I receive for services rendered to me immediately upon receipt. I agree to allow the health care provider to release information to the Arizona State Immunization Information System (ASIIS) to record that I (or for the person for whom I am authorized to consent) have received this COVID-19 vaccine. This information will help keep track of the manufacturer and I have had a copy of the Emergency Use Authorization for the COVID-19 vaccine made available to me. I have had a chance to ask questions and I believe I understand the benefits and risks of the COVID-19 vaccines requested. I ask that the vaccines be administered to me or the person for whom I am authorized to make this request. Patient Printed Name Patient Signature Date Signed Authorized Person's Printed Name (if applicable) Authorized Person's Signature Vaccine Administration Information for Immunizer Use Only Manufacturer Administration Date LEFT ARM RIGHT ARM **Expiration Date** Administering Immunizer Name and Title Administering Immunizer Signature

Vaccine Administration Screening Checklist

 CDC Pre-Vaccination Checklist is also available in <u>Spanish</u>



or vaccine recipients: Patient	Name			
he following questions will help us determine if there is ny reason you should not get the COVID-19 vaccine today. If you answer "yes" to any question, it does not necessarily mean you hould not be vaccinated. It just means additional questions may be asked. a question is not clear, please ask your healthcare provider to explain it.	Age	Yes	No	Don't
Are you feeling sick today?				T
2. Have you ever received a dose of COVID-19 vaccine?				
If yes, which vaccine product did you receive? Pfizer	☐ Another product			
would also include an allergic reaction that occurred within 4 hours that caused hives, swe A component of a COVID-19 vaccine including either of the following: Polyethylene glycol (PEG), which is found in some medications, such preparations for colonoscopy procedures		wheezing,		
O Polysorbate, which is found in some vaccines, film coated tablets, ar	nd intravenous steroids.			
A previous dose of COVID-19 vaccine.				
 A vaccine or injectable therapy that contains multiple components, or vaccine component, but it is not known which component elicited the 				
4. Have you ever had an allergic reaction to another vaccine (other than CC injectable medication? (This would include a severa allergic reaction [e.g., anaphylaxis] that required treatment we caused you to go to the hospital. It would also include an allergic reaction that occurred wis welling, or respiratory detixes, including whereting.)	ith epinephrine or EpiPen* or that			
5. Have you ever had a severe allergic reaction (e.g., anaphylaxis) to sometl of COVID-19 vaccine, or any vaccine or injectable medication? This would environmental, or oral medication allergies.				
6. Have you received any vaccine in the last 14 days?				
				_
7. Have you ever had a positive test for COVID-19 or has a doctor ever told you	that you had COVID-19?			

IAC COVID-19 mRNA Vaccine Comparison Chart

- Side-by-side view of Moderna and Pfizer
- Every angle of the two for a quick reference

COVID-19 mRNA Vaccines



What Clinic Personnel Need to Know

	Pfizer-BioNTech	Moderna
Product	Pfizer-BioNTech COVID-19 Vaccine (BNT162b2)	Moderna COVID-19 Vaccine (mRNA-1273)
Vaccine type	mRNA (messenger RNA)	mRNA (messenger RNA)
Age indication	16 years of age and older	18 years of age and older
Basic information	CDC Resources: Pfizer-BioNTech COVID-19 Overview www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/ index.html	CDC Resources: Moderna COVID-19 Overview www.cdc.gov/vaccines/covid-19/info-by-product/ moderna/index.html
	ACIP Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine www.dc.gov/mmm/volumes/69/wr/mm6950e2.htm?s_cid=mm6950e2.	ACIP Interim Recommendation for Use of Moderna COVID-19 Vaccine www.cdc.gov/mmwr/volumes/69/wr/mm695152e1. htm?s_cid=mm695152e1_w
	Pfizer-BioNTech Resources: Pfizer-BioNTech COVID-19 vaccine website www.cvdvaccine-us.com	Moderna Resources: Moderna COVID-19 vaccine website www.modernatx.com/covid19vaccine-eua/providers/
Emergency Use Authorization (EUA)	For Providers www.fda.gov/media/144413/download	For Providers www.fda.gov/media/144637/download
factsheets Required to be given to recipients in place of a Vaccine Information Statement (VIS)	For Recipients and Caregivers English www.fda.gov/media/144414/download Translations www.fda.gov/emergency-preparedness-and-response/ coronavirus-disease-2019-covid-19/pfizer-biontech- covid-19-vaccions	For Recipients and Caregivers English www.tda.gov/media/144638/download Translations www.fda.gov/emergency-preparedness-and-response/ coronavirus disease-2019-covid-19/moderna-covid- 19-vaccine
Presentation	Frozen liquid concentrate, no preservative Multidose vial, at least 5 doses/vial* Some syringe types may be able to draw up to 6-7 full doses per vial, which is acceptable. Never combine vaccine from more than 1 vial to make a dose.	Frozen liquid, no preservative Multidose vial, at least 10 doses/vial* Some syringe types may be able to draw up 11 full doses per vial, which is acceptable. Never combine vaccine from more than 1 vial to make a dose.
Packaging	• 195 vials/tray (975 doses) • 1–5 trays per shipper • Each tray: 9" x 9" x 1.6"	• 10 vials/carton (100 doses) • Each carton: 2" x 2" x 5-3/8"
Minimum shipment	975 doses (195 multidose vials)	100 doses (10 multidose vials)

CONTINUED ON THE NEXT PAGE



COVID-19 Vaccine: Quick Reference Guide for Healthcare **Professionals**

Product Information for all U.S. COVID-19 vaccines





distress (e.g., wheezing, stridor), or anaphylas a consultation from the Clinical Immunication S these individuals should only be done in an appr People with a contraindication to mRNA CC previously received an mRNA COVID-19 va-People with a contraindication to Japasen (

03/26/2021 (13216294)





The table below provides basic information on the proper storage, preparation, and administration of the currently authorized COVID-19 vaccing

		Pfizer	Moderna	Janssen	
GENERAL STORAGE & HAND	EUA	www.fda.gov/emergency- preparedness-and-response/ coronavirus-disease-2019-covid-19/ pfizer-biontech-covid-19-vaccine	www.fda.gov/emergency- preparedness-and-response/ coronavirus-disease-2019-covid-19/ moderna-covid-19-vaccine	www.fda.gov/emergency- preparedness-and-response/ coronavirus-disease-2019- covid-19/janssen-covid-19-vaccin	
	CDC Vaccine Information	www.cdc.gov/vaccines/covid-19/ info-by-product/pfizer/index.html	vrww.cdc.gov/vaccines/covid-19/ info-by-product/moderna/index. html	www.cdc.gov/vaccines/ covid-19/info-by-product/ janssen/index.html	
	Manufacturer Contact information	Website: www.cvdvaccine.com Medical information: 800-438-1985 Customer service: 800-879-3477	Website: www.modernatx.com Medical Information: 866-663-3762	Website: www.vaxcheck.inj. Medical information: 1-800-565-4008	
	How supplied	Multidose vial: 6 doses	Multidose vial: 10 doses	Multidose vial: 5 doses	
	Diluent	0.9% sodium chloride (preservative-free, normal saline) provided in the ancillary kit. Do NOT use other diluent.	None	None	
	Storage Temperatures: Before Puncture	Between: -80°C and -60°C (-112°F and -76°F) until the expiration date -25°C and -15°C (-13°F and 5°F) for up to 2 weeks 2°C and 8°C (36°F and 46°F) for up to 120 hours (5 days)	Between: -25°C and -15°C (-13°F and 5°F) until the expiration date 2°C and 8°C (36°F and 46°F) for up to 30 days	Between: 2°C and 8°C (36°F and 46°F) until the expiration date.	
	Storage Temperatures: After puncture	Between: 2°C to 25°C (36°F to 77°F) for up to 6 hours. Discard any unused vaccine after 6 hours.	Between: 2°C and 25°C [36°F and 77°F] for up to 6 hours. Discard any unused vaccine after 6 hours.	Between: 2°C and 8°C (36°F and 46°F) for up to 6 hours. 9°C and 25°C (47°F and 77°F) fo up to 2 hours.	
L		6 nours.	nours.	Discard any unused vaccine after these time frames	
N G	Transport Temperatures: Before Puncture	Between: -80°C and -60°C (-112°F and -76°F) -25°C and -15°C (-13°F and 5°F)	Between: -25°C and -15°C (-13°F and 5°F) 2°C and 8°C (36°F and 46°F) for up	Between: 2°C and 8°C (36°F and 46°F)	
		2°C and 8°C (36°F and 46°F)	to 12 cumulative hours.		
	After Puncture	Between: 2°C to 25°C (36°F to 77°F) for up to 6 hours.	Between: 2°C and 25°C (36°F and 77°F) for up to 6 hours.	Between: 2°C and 8°C (36°F and 46°F) for up to 6 hours	
	Type of Vaccine	mRNA	mRNA	Viral vector	
	Age Indications	16 years of age and older	18 years of age and older	18 years of age and older	
	Schedule	2-doses, separated by 21 days. Both doses must be Pfizer- BioNTech vaccine	2 doses, separated by 28 days. Both doses should be Moderna vaccine	1 dose only	
	Dosage	0.3 mL	0.5 mL	0.5 mL	
	Needle gauge/length	22-25 gauge, 1 - 115"	22-25 gauge, 1 - 11/2"	22-25 gauge, 1 - 11/2"	

03/26/2021 CS32162949

Standing Order Links

Link to Moderna

Link to Pfizer

Link to lanssen

Moderna COVID-19 Vaccine Standing Orders for Administering Vaccine

to Persons 18 Years of Age and Older



Note: For more information/quidance, please contact the immunization program at your state or local health department or the appropriate state body (e.g., state board of medical/nursing/pharmacy practice).

 To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP).

· Where authorized under state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess and vaccinate persons who meet the criteria in the "Procedure" section below without the need for clinician examination or direct order from the attending provider at the time of the interaction

- Moderna COVID-19 Vaccine based on the
- o Has not completed a COVID-19 vaccination series, regardless of brand. If 2 doses of an mRNA vaccine have been administered or a single dose of Janssen vaccine has been administered, no additional doses are recommended
- o If the recipient has received 1 previous dose of Moderna COVID-19 Vaccine, administer the second dose at an interval of least 28 days (but preferably before 42 days).
- o. If the vaccine product given as the first dose cannot be determined or is no longer available, any mRNA COVID-19 vaccine product may be administered at least 28 days after the
- Do not administer Moderna COVID-19 Vaccine at the same time as other vaccines. Separate Moderna COVID-19 Vaccine by 14 days before or after the administration of other vaccines.
- Defer vaccination with Moderna COVID-19 Vaccine for at least 90 days for persons who received passive antibody therapy (monoclonal antibodies or convalescent plasma) as part of
- If the recipient has a history of dermal filler use, advise them to contact their healthcare provider for evaluation if they develop swelling at or near the dermal filler site following vaccination.

Assess persons 18 years of age and older for vaccination with Screen for contraindications and precautions.

- » Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of an mRNA COVID-19 vaccine (Moderna or Pfizer-RioNTech)
- » Immediate allergic reaction* of any severity to a previous dose or known (diagnosed) allergy to a component of the vaccine (see Table 1 in this document for a list of vaccine components)

Note: Persons who have a contraindication to an mRNA COVID-19 vaccine (Moderna or Pfizer-RighTech) may be able to receive the Janssen COVID-19 Vaccine (see footnote) *

- » History of an immediate allergic reaction* to any other vaccine or injectable therapy (i.e., intramuscular, intravenous, or subcutaneous vaccines or theranies)
- . This includes persons with a reaction to a vaccine or injectable therapy that contains multiple components, one of which is polyethylene glycol (PEG) or another vaccine component, but for whom it is unknown which componen elicited the immediate allergic reaction.
- . People with a contraindication to Janssen COVID-19 Vaccine have a precaution to both mRNA vaccines (see footnote).

Moderate to severe acute illness

Pfizer-BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 16 Years of Age and Older



Note: For more information/quidance, please contact the immunization program at your state or local health department or the appropriate state body (e.g., state board of medical/nursing/pharmacy practice).

 To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by varcinating persons who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP).

- Assess persons 16 years of age and older for
- Has not completed a COVID-19 vaccination series, regardless of brand. If 2 doses of an mRNA vaccine have been administered or a single dose of Janssen vaccine has been administered, no additional doses are
- o If the recipient has received 1 previous dose of Pfizer-BioNTech COVID-19 Vaccine, administer the second dose at an interval of least 21 days (but preferably before 42 days),"
- o If the vaccine product given as the first dose cannot be determined or is no longer available, any mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose
- Vaccine at the same time as other vaccines 14 days before or after the administration of

 Where authorized under state law, standing orders enable eligible nurses and other healthcare professionals (e.g. pharmacists) to assess and vaccinate persons who meet the criteria in the "Procedure" section below without the need for clinician examination or direct order from the attending provider at the time of the interaction.

- vaccination with Pfizer-BioNTech COVID-19 Vaccine based on the following criteria:
- recommended

- Do not administer Pfizer-BioNTech COVID-19 Separate Pfizer-BioNTech COVID-19 Vaccine by other vaccines.1
- Defer vaccination with Pfizer-BioNTech COVID-19 Vaccine for at least 90 days for persons who received passive antibody therapy (monoclonal antibodies or convalescent placma) as part of COVID-10 treatment

- If the recipient has a history of dermal filler use, advise them to contact their healthcare provider for evaluation if they develop swelling at or
- near the dermal filler site following vaccination. Screen for contraindications and precautions.
- Contraindications:
- » Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of an mRNA COVID-19 vaccine (Moderna or
- Immediate allergic reaction[±] of any severity to a previous dose or known (diagnosed) allergy to a component of the vaccine (see Table 1 in this document for a list of vaccine components)

Note: Persons who have a contraindication to the mRNA COVID-19 vaccine (Moderna or Pfizer-BioNTech) may be able to receive the Janssen COVID-19 Vaccine (see footnote).*

o Precautions

- History of an immediate allergic reaction[±] to any other vaccine or injectable therapy (i.e., intramuscular, intravenous, or subcutaneous vaccines or therapies)
- . This includes persons with a reaction to a vaccine or injectable therapy that contains multiple components, one of which is polyethylene glycol (PEG) or another vaccine component, but for whom it is unknown which component elicited the immediate allergic reaction.
- People with a contraindication to Janssen COVID-19 Vaccine have a precaution to both mRNA vaccines (see footnote)# Moderate to severe acute illness
- Provide all recipients with a copy of the current federal Emergency Use

Janssen COVID-19 Vaccine (Johnson & Johnson)

Standing Orders for Administering Vaccine to Persons 18 Years of Age and Older



Note: For more information/quidance, please contact the immunization program at your state or local health department or the appropriate state body (e.g., state board of medical/nursing/pharmacy practice).

 To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP)

 Where authorized under state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess and vaccinate persons who meet the criteria in the "Procedure" section below without the need for clinician examination or direct order from the attending provider at the time of the interaction.

- Assess persons 18 years of age and older for vaccination with Janssen COVID-19 Vaccine based on the following criteria:
 - Has not completed a COVID-19 vaccination series. renardless of brand
 - The Janssen COVID-19 Vaccine requires 1 dose. No additional doses are needed.
 - If the recipient has received 1 previous dose of an mRNA vaccine, the same brand should be administered for the second dose
 - In situations where the first dose of an mRNA COVID-19 vaccine was received but the patient is unable to complete the series with either the same or different mRNA COVID-19 vaccine (e.g., due to contraindication) consideration may be given to vaccination with Janssen COVID-19 Vaccine at a minimum interval of 28 days from the mRNA COVID-19 vaccine dose. However, vaccination should be done in an appropriate setting under the supervision of a healthcare provider experienced in the management of severe allernic reactions. Consider referral to an allergist-immunologist. See footnote for further information on administering Janssen COVID-19 Vaccine to persons with a contraindication to mRNA COVID-19 vaccines
- Janssen COVID-19 Vaccine should not be administered at the same time as other vaccines. Administer the vaccine alone, with a minimum interval of 14 days before or after administration of any other vaccine

- Screen for contraindications and precautions
- o Contraindications
- Severe allergic reaction (e.g., anaphylaxis) to a component of
- Immediate allergic reaction† of any severity or known (diagnosed) allergy to a component of the vaccine (see Table 1 in this document for a list of ingredients in COVID-19 vaccines)

Note: Persons who have a contraindication to Janssen COVID-19 Vaccine may be able to receive an mRNA COVID-19 vaccine (see footnote).4


- History of an immediate allergic reaction to any other vaccine or injectable therapy (i.e., intramuscular, intravenous, or subcutaneous vaccines or therapies)
- . This includes persons with a reaction to a vaccine or injectable therapy that contains multiple components, one of which is polysorbate or another vaccine component. but for whom it is unknown which component elicited the immediate allergic reaction.
- People with a contraindication to an mRNA COVID-19 vaccine have a precaution to the Janssen COVID-19 Vaccine (see footnote).*
- Moderate to severe acute illness
- Provide all recipients with a copy of the current federal Emergency Use Authorization (EUA) Fact Sheet for Recipients and Caregivers.
- Prepare to administer the vaccine. Choose the correct needle

*Administrat the second dose as close as possible to the recommended interval (28 days). If the second dose is not administered within 42 days of the first dose, the series dose not need to be restarted. Doses inadvertently administered less than 28 days apart do not need to be repated.

CDC Expiration Date Tracking Tool

The CDC expiration date tracking tool can be used for doses placed in the refrigerator.

- Pfizer doses can only be refrigerated for up to 5 days.
- Moderna doses can be refrigerated for up to 30 days.
- Janssen doses can be refrigerated for up to 3 months.



COVID-19 Vaccine Number of Doses

- Additional doses can be drawn from the Moderna vial and J&J vials
- Guidance and expectation is that ONLY the approved number of doses should be drawn up
- Scheduling of patients should be based on the approved number of doses, not the additional doses

Vaccine Dosages

	Doses/vial	Volume	Ancillary Content
Pfizer	6	0.3 mL	6 doses/vial
Moderna	10	0.5 mL	10 doses/vial
J&J	5	0.5 mL	5 doses/vial
Rules	 Administer only full doses Never try to pool vials to make a full dose Do not refreeze any COVID vaccines. 		

"CDC recommends healthcare providers follow the dosing guidance from the manufacturer and outlined in the EUA. CDC will update its guidance if the EUA and ancillary supply kits support additional doses per vial in the future."



Vaccine

Pfizer-BioNTech COVID-19 Vaccine

Vaccine Storage

Ultra-Cold Temperature Freezer



- -80.0°C to -60.0°C
- Store for up to 6 months

Thermal Shipping Container with Dry Ice Pellets



- Will maintain -80.0°C to -60.0°C for up to 30 days upon re-icing
- Up to 6 re-icings are authorized
- 1st re-icing within 24 hours of initial inspection
 - · Dry ice pellets will be provided for 1st re-icing
- Re-icings required every 5 days after the 1st re-icing to maintain temperature
- May only be opened up to 2 times per day (≤ 3 minutes per opening)

Freezer

• -25.0°C to -15.0°C



- Store for up to 2 weeks
- May be returned one time to the recommended storage condition of -80.0°C to -60.0°C

Refrigerator



- 2.0°C to 8.0°C
- · Store for up to 5 days



Disclaimer: Subject to change due to FDA EUA approval

Pfizer-BioNTech COVID-19 Vaccine

Thawing



- When removing from ultra-cool temperature:
 - Thaw at 2.0°C to 8.0°C for 3 hours OR
 - Thaw at room temperature for 30 minutes
- Thawed vaccine must be diluted within 2 hours
- If unable to dilute, store at 2.0° C to 8.0° C (up to 5 days)
- DO NOT open vial trays or remove vials until ready for thawing or use

Vaccine and Diluent



- Use 1 vial for every 6 recipients (6-dose vial)
- Dilute a single thawed vial with 1.8mL of 0.9% Sodium Chloride Injection, USP (supplied with ancillary kit)
 - · DO NOT USE ANY OTHER DILUENT
 - · DO NOT shake vial upon dilution
 - · Gently mix by turning vial over and back 10 times
- · Must use diluted vaccine within 6 hours
- · Discard any unused, diluted vaccine after 6 hours

Administration



- Draw 0.3mL of diluted vaccine and inject intramuscularly (IM) in the deltoid muscle
- · Second dose due 21 days later
- For individuals 16 and older
- Pregnant/lactating women can choose to be vaccinated talk with your healthcare provider
- Not for children

The information on the Full EUA Prescribing Information regarding the number of doses per vial after dilution supersedes the number of doses stated on vial labels and cartons.



Disclaimer: Subject to change due to FDA EUA approval


Pfizer's Additional 6th Dose Now Approved, EUA Amended

- Ancillary kit supports 1170 doses
- If you only get 5 doses out of a 6 dose vial, you will need to count the 6th dose as wasted
- 5:1 ratio of low dead volume (LDV) syringes to non-LDV syringes to ensure extraction of the 6th dose
- Ancillary kits have 1000 LDV syringes and 240 non-LDV syringes to support 5:1 ratio
- Each dose must contain 0.3 mL of vaccine
- If the amount in the vial cannot provide a full sixth dose of 0.3 mL, the vial and content should be discarded
- Excess vaccine should never be pooled from multiple vials to make up a full dose
- The NDC number will not change

Pfizer COVID-19 Vaccine Expiration Dates and Lot

Numbers

- The label on the right is from the tray
- Lot number is highlighted in yellow
- Expiration date below lot number
- MM/YYYY format
- Exp date on vial circled in red





the vaccine at

(35°F to 77°F).

Discard after 6 hours.

EK5730

2°C to 25°C

Contains no preservative.

STORAGE: Prior to cilution, store at

Store in this carton to protect from light.

After dilution, each viel contains 5 doses of 0.3 mL. See FDA-authorized Fact Sheet or scan 08 code

-80°C to -60°C (-112°F to -78°F).

DOSAGE AND ADMINISTRATION:


COVID-19 Vaccine (Pfizer)

Pfizer EUA Website - cvdvaccine.com

- EUA factsheet for providers
- EUA factsheet to give to patients

<u>cvdvaccine-us.com/resources</u>


- Reference sheets
- Videos
- Checklist for storage and handling
- Helpful links



CDC Pfizer Resource

Pfizer-BioNTech COVID-19 Vaccine Information

- Storage & handling requirements
- Administration requirements
- Expiration date tracking tool
- Dry ice safety
- Beyond Use Date (BUD) Label



refrigerator between 2°C and Remove vaccine vials from

hours (5 days).

» Storing Vaccine in th

Pfizer-BioNTech COVID-19 Va

- Complete the information and attach it to the contai holding the vaccine vials.
- Once labeled, store the var between 2°C and 8°C (36'
- As the 120-hour (5-day) de manufacturer for guidano the vaccine. If directed to

» Deliveries

Vaccine

Use CDC's Delivery Checklist for F When vaccine is delivered:

- 1. Open the thermal shipping shipment button on the ten device for 5 seconds.
- 2. The LED indicator light will cl temperature status report wi who ordered the vaccine.
- 3. Proceed based on the color o No color or red: Wait for the Green: Unpack the vaccine.

Dry Ice Safety

- 1. Dry ice is needed to mainta the thermal shipping conta
- 2. Ensure staff has proper PPI dry ice safely.

Ancillary Supply Kit

- An ancillary supply kit will be del
- Mixing supplies: Diluent, need alcohol prep pads
- Mixing supplies are package identification label.

General Information » Age Indications

16 years of age and older »Schedule

2-dose series separated by 21 days

Intramuscular (IM) injection in the deltoid muscle

Vaccine: COVID-19 vaccine (Pfizer) Diluent: 0.9% sodium chloride (normal saline, preservative-free)

A series started with COVID-19 vaccine (Pfizer) Multidose vial: 6 doses per vial should be completed with this product. Dosage: 0.3 mL » Administration

Vaccine MUST be mixed with diluent » Thawing Frozen Vaccine

- Frozen vaccine must be thawed before using. Thaw vaccine in the refrigerator or at room temperature:
- · Refrigerator: Between 2°C and 8°C (36°F and 46°F) Unpunctured vials may be stored in the refrigerator for up to
- 120 hours (5 days). Room temperature (for immediate use): Up to 25°C (77°F)
- Unpunctured vials cannot be kept at room temperature for more than 2 hours (including thaw time).

Amount of time needed to thaw vaccine varies based on

- temperature and number of vials Do NOT refreeze thawed vaccine.
- Use vials in the refrigerator before removing vials from ultracold temperature or freezer storage
- Use CDC's beyond-use date labels for this vaccine to track storage time at refrigerated and frozen temperatures.

Prepare the Vaccine

Follow aseptic technique. Perform hand hygiene before vaccine preparation, between patients. when changing gloves (if worn), and any time hands become soiled."

Remove vaccine from the freezer or refrigerator. Allow vaccine to come to room temperature. Vials can be held at room temperature for up to 2 hours before mixing.

Before mixing, check the expiration dates of the vaccine and diluent NEVER use expired vaccine or diluent. The expiration dates for the diluent and the vaccine are located on the respective vials.

With the vaccine at room temperature, gently invert vial 10 times. Do not shake the vial. If the vial is shaken, contact the manufacturer. The vaccine is white to off-white in color and may contain opaque particles. Do not use if liquid is discolored. Using a new, sterile alcohol prep pad for each v



Inject 1.8 mL 0.9% sodium chloride (normal saline, preservative-free) diluent into the vaccine vial





Gently invert the vial containing vaccine and diluent 10 times. The vaccine will be off-white in color. Do not use if discolored or contains particulate matter. Do not shake. If the vial is shaken, contact the manufacturer



Note the date and time the vaccine was mixed on the vial.



Sites who do not use their Pfizer shippers for on-site storage should opt-out of on-site temperature monitoring

You need to reply to the email received from Controlant after initially opening the Pfizer shipper box

To do this properly sites need to:

- 1. Validate the primary contact email registered is correct before ordering COVID vaccines
- 2. Confirm receipt of the Controlant email after Pfizer vaccine delivery
- 3. Reply appropriately to the email

Email will come from onsitemonitoring@controlant.com

Moderna Vaccine Reference Sheet

Moderna COVID-19 Vaccine

Vaccine Storage

Freezer



- -25.0° C to -15.0° C
- -13.0° F to 5.0° F
- Store in freezer for up to 6 months
 Room Temperature: up to 12 hours

Refrigeratoı



- 2.0° C to 8.0° C
- 36.0° F to 46.0° F
- Store in refrigerator for up to 30 days if vial is not entered
- DO NOT REFREEZE
- Room Temperature: up to 12 hours

Dosage



- Each vaccine vial contains 10, 0.5mL doses to be administered
- · No dilution required
- Discard any punctured vial after 6 hours

Administration



- Standard needles and syringes
- Draw 0.5mL and inject intramuscularly (IM)
- Second dose due 28 days later
- For adults 18 and over
- Pregnant/lactating women can choose to be vaccinated talk with your healthcare provider
- Not for children

The storage and handling information found on the Fact Sheet supersedes the storage and handling information on the carton and vial labels.




Disclaimer: Subject to change due to FDA EUA approval

Moderna Vaccine

24/7 Call Center:

1-866-MODERNA (1-866-663-3762)


Moderna Temperature Excursion Tool



moderna Moderna COVID-19 Vaccine GO TO FULL UNITED STATES SITE HERE: For US Vaccine Recipients For US Vaccination Providers The Moderna COVID-19 Vaccine has not been approved or licensed by the US Food and Drug Administration (FDA), but has been authorized for emergency use by FDA, under an Emergency Use Authorization (EUA), to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 18 years of age and older. There is no FDA-approved vaccine to prevent COVID-19. The EUA for the Moderna COVID-19 Vaccine is in effect for the duration of the COVID-19 EUA declaration justifying emergency use of the product, unless the declaration is terminated or the authorization is revoked sooner. Download EUA Fact Sheet & Download EUA Fact Sheet for Look Up Vaccine Expiration Vaccine Recipients & Caregivers Full PI for Vaccination Providers Dates For Vaccination Providers

Moderna COVID-19 vaccine expiration dates

- Moderna will not have an expiration date on the vial/box
- Use QR code to look up the expiration date on <u>Moderna's</u> website
- Look up the expiration date using the lot number



Moderna COVID-19 Vaccine Information | CDC

- Storage and Handling Summary
- BUD Guidance and Labels
- Storage and Handling Labels
- Vaccine Expiration Date Tracking Tool
- Freezer Storage Loggers (F) and (C)
- Prep and Administration Summary
- Standing Orders Template



Janssen Vaccine Reference Sheet

- 1 dose
- 2-8° C refrigerator for up to 3 months

Janssen COVID-19 Vaccine

Vaccine Storage

Refrigerator



- 2.0° C to 8.0° C
- 36.0° F to 46.0° F
- Store in refrigerator for up to 3 months
- DO NOT REFREEZE

Dosage



- Each vaccine vial contains 5, 0.5mL doses to be administered
- No reconstitution required
- Discard any punctured vial held at refrigerator temperatures after 6 hours
- Discard any punctured vial held at room temperature (maximally 25°C/77°F) after 2 hours"

Administration



- Standard needles and syringes
- Draw 0.5mL and inject intramuscularly (IM)
- Single dose
- · For adults 18 and older
- Not for children


The storage and handling information found on the Fact Sheet supersedes the storage and handling information on the carton and vial labels.



Disclaimer: Subject to change due to FDA EUA approval

Janssen COVID-19 Vaccine Website

- Janssencovid19vaccine.com
- FDA Emergency Use Authorization Letter
- Expiration date info
- Adverse Event Reporting
- Janssen Temperature
 Excursion Tool




Janssen COVID-19 Vaccine Expiration Date

- Vial will have QR code
- Expiry Checker
- <u>Janssen Temperature Excursion Tool</u>

Expiry Checker: Janssen COVID-19 Vaccine Under Emergency Use Authorization

Thank you for using the Janssen COVID-19 Vaccine expiry checker. Please enter the lot number found on the product carton or vial to obtain its expiration date. If you have product questions, please contact us.

Enter Lot #: [e.g. ABC123] Check Lot



Janssen COVID-19 Vaccine (Johnson & Johnson) | CDC Resource

- EUA
- Administration
- Storage and Handling
- FAQs
- Interim Considerations



Ancillary Kits

- Shipped separately from vaccines
- Will arrive before or on same day as vaccines

Each kit will include:

- Needles (various sizes for the population served by the ordering vaccination provider)
- Syringes
- Alcohol prep pads
- 4 Surgical masks and face shields for vaccinators
- COVID-19 vaccination record cards for vaccine recipients
- Needle information card

Return Thermal Shipping Containers

Pfizer

- Turn off the temperature monitoring device
- Return the shipping containers and temperature monitors
- Return label included with the box
- <u>Informative video</u> on returning the Pfizer thermal shipper

Moderna

Return using the return label located on the inside of the box

Janssen shippers do not need to be returned

2 phases for vaccine distribution

Phase 1

- The doses are allocated to local jurisdictions (county health departments and tribal allocators)
- Limited number of vaccines available
- Target <u>ACIP recommended populations</u>

Phase 2

- Doses may be **ordered** by providers in ASIIS to administer the vaccines
- Target <u>ACIP recommended populations</u>

Vaccine Process Phase 1

Process when vaccines are limited

- CDC allocates doses to State
- State allocates doses to county health department/tribal jurisdictions
- Jurisdictions allocate doses to providers
- AIPO enters/approves the orders in ASIIS
- Order goes to CDC to Distributor/Manufacturer
- Order is shipped (will show in ASIIS)
- Provider receives shipment of ancillary kit and vaccine (may not be same day)
- Provider logs into ASIIS to mark doses as "received"
- Provider administers vaccine
- Provider reports the administered vaccine to ASIIS through their EHR, State VMS POD application, directly in ASIIS or using Mass Immunization Module in ASIIS
- The dose is subtracted from the ASIIS inventory

Vaccine Process Phase 2

Process when vaccines are widely available

- Providers enter COVID-19 vaccine order in ASIIS
- AIPO will approve the order
- Order goes to CDC to Distributor/Manufacturer
- Order is shipped (will show in ASIIS)
- Provider receives shipment of ancillary kit and vaccine (may not be same day)
- Provider logs into ASIIS to mark doses as "received"
- Provider administers vaccine
- Provider reports the administered vaccine to ASIIS through their EHR, State VMS POD application, directly in ASIIS or using Mass Immunization Module in ASIIS
- The dose is subtracted from the ASIIS inventory


Communication Resources

Ad Council COVID-19 Vaccination Campaign: It's Up to You

<u>Creative materials</u> that can be shared/used by providers

getvaccineanswers.org

- Campaign site for consumers
- Answers common questions
- Provides vaccine information
- Link to Spanish site -<u>www.DeTiDepende.org</u>




COVID-19 Vaccination Communication Toolkits

- For Medical Centers, Clinics, Pharmacies, and Clinicians
- For Healthcare Professionals and Pharmacists
- For LTCF Administrators and Leadership
- For Employers of Essential Workers
- For Staff of Organizations Serving Communities

The toolkit contains a variety of resources that you can use virtually or in person (with proper COVID-19 safety precautions):

- Introductory letter
- Posters
- FAQ
- Key messages
- Slide decks

Provider Resources for Patient Conversations About COVID-19 Vaccines





Talking to Recipients about COVID-19 Vaccines

Many people have questions about the new coronavirus disease 2019 (COVID-19) vaccines. As vaccine recipients' mosttrusted source of information on vaccines, you play a critical role in helping them understand the importance of COVID-19 vaccination, as well as if and when it is likely to be recommended for them.

The materials below include proven communication strategies and tips for effectively setting expectations and addressing questions from COVID-19 vaccine recipients.



Making a Strong Recommendation for COVID-19 Vaccination



Answering Vaccine Recipients' Ouestions




Understanding and Explaining COVID-19 Vaccines

Background and safety information for healthcare professionals and other vaccine providers, as well as tips for explaining the vaccines to patients.

- mRNA COVID-19 Vaccines
- Viral Vector COVID-19 Vaccines

HHS Video "Tell Me More About Vaccines"

The video answers commonly asked questions about the COVID-19 vaccine. The video shares why vaccines are so important and provides expert commentary and graphic illustration to help viewers understand the science of vaccine development. Tune in to hear from various experts, including Dr. Anthony Fauci (NIH), Dr. Stephen Hahn (FDA), and Dr. Robert Kadlec (ASPR), on the steps researchers and scientists are taking to develop a safe and effective vaccine. You are encouraged to add the video link to your website or promote it on social media.



FDA Emergency Use Authorization for Vaccines Explained

- What is an Emergency Use Authorization?
- Are the COVID-19 vaccines rigorously tested?
- What safety and effectiveness data are required to be submitted to FDA for an EUA request for a vaccine intended to prevent COVID-19?
- Link to **Spanish page** at the top of the article

CDC COVID-19 Vaccine Web Pages for the general public

- Benefits of Getting a COVID-19 Vaccine
- How COVID-19 Vaccines Work
- Myths and Misconceptions about COVID-19
 Vaccines
- <u>Frequently Asked Questions about COVID-19</u>
 <u>Vaccination</u> (newly expanded)
- <u>Understanding MRNA vaccines</u>
- What to Expect at Your Appointment to Get Vaccinated for COVID-19
 - Translated in many languages



ASIIS Information

<u>Correcting Negative Doses in ASIIS</u>

Reconciling ASIIS inventory

- Giving more doses than what is in the ASIIS inventory will make the inventory negative, which will mean you cannot submit inventory reconciliation
- AIPO Train module: Correcting Negative COVID-19 Doses in ASIIS

If your ASIIS Inventory is not accurate

- Doses that have been administered to patients should not be removed from the Reconciliation page (Inventory) in ASIIS
- Troubleshoot why the doses did not decrement
 - Register for Dose Accountability Webinar in AIPO Train
 - Past Dose Accountability Webinar videos in course module
- <u>Job aid</u> to walk you through process of searching/adding/editing patient records manually in ASIIS

Mark doses as *Received* in ASIIS when the doses arrive

- Required regardless what system you use to document vaccine administration (EHR, VMS, ASIIS)
- When the doses arrive, mark them as **Received** in ASIIS
 - Log into ASIIS
 - Go to Orders/Transfers> Create/View Orders> Select arrow for Inbound Order/Transfer
 - Verify the expiration date, lot number, and quantity of doses
 - ASIIS may show 12/31/2069 as a placeholder and you must change it
 - Click the **Receive** button to receive the doses into the ASIIS Inventory
- After the doses are **Received** in ASIIS, you may administer them
- If you administer doses before they are Received into the ASIIS inventory, they will not decrement from the ASIIS inventory

Order Details								
Shipped Quantity	Receipt Quantity	Rejected Quantity	Vaccine	Funding Source	Manufacturer	Lot Number	Expiration Date	Reason for Rejecting
300	300		COVID-19, mRNA, LNP-S, PF, 100 mcg/ 0.5 mL dose	PAN	MODERNA US,IN ✔	ABC123	12/31/2069	select
Comments	8					Tracking #		_
								Cancel Receive

Expiration Dates

- ASIIS may show 12/31/2069 as a placeholder and you must change it when marking the doses as *Received* in ASIIS
- The expiration date is for doses placed in the proper freezer type
 - Doses placed in the refrigerator or drawn up must be used more quickly



Funding Source - PAN

- The funding source should be PAN.
- If you have an EHR, your EHR vendor should <u>send the code VXC50</u>. On the user interface side, you will select PAN when administering.
- If you select VFC, State, Private, or something else as the funding source, the doses will not decrement from the ASIIS inventory.

FAQs

FAQs

Q: If I am a VFC provider and already have an ASIIS PIN, do I need to onboard?

• A: Yes. If a facility location wants to administer COVID-19 vaccines, they will need to onboard and sign the CDC COVID-19 Agreement. The VFC Program and the COVID-19 vaccine program are separate programs with separate signed Agreements.

Q: How do I order COVID-19 vaccines in ASIIS?

• A: Because we are in phase 1 of vaccine allocation, you will not be able to order COVID-19 vaccines in ASIIS. Once we enter Phase 2, you will be able to place orders.

Q: Where can I find these slides?

• A: These slides can be found at azdhs.gov/covid19vaccine under Provider Resources

THANK YOU!